Supply Chain Planner, 12 Months Maternity Cover

Job description:

We use science to save lives, and so can you.

We are currently recruiting for a Supply Chain Planner to join the Warehouse and Supply Chain (WSC) team to cover a period of 12 months. The purpose of this role is to oversee the product supply chain operation from forecasting to obsoletion of products.

Our Warehouse and Supply Chain team are critical to our Manufacturing success. They make sure we have the consumables and reagents needed to make our products, which will go on to change the lives of millions of patients. This multi-functional team works together to support all our logistics needs.

Your responsibilities in this role would be:

• Ensuring vendor orders are placed on a timely and scheduled basis and ensure stock levels are maintained


• Liaising with suppliers to ensure product orders are delivered on time and in full, as well as resolving or escalating any issues


• Working closely with account handlers and other departments to ensure forecasts are accurately maintained


• Maintaining system integrity – part creation, units of measure, purchasing and issuing pack size & maintaining timely transactions to allow for successful performing of MRP


• To control and monitor inventory accuracy. Including cycle counts, annual stock check. Review excess and obsolete stock levels- taking appropriate actions


• Ensuring all requests for inventory are actioned on time and in full. Work closely with all internal departments to ensure the highest standards of customer service are met.


• Raising documentation within the Quality Management system to ensure the company standards for compliance are met.


• Administrative support of the function.

Profile description:

We are looking for:

• Educated to GCSE Maths & English or equivalent.


• Previous experience within materials management & supply chain administration.


• Demonstrable supplier collaboration & problem-solving skills.


• Computer Literacy skills and knowledge with Enterprise Resource Planning (ERP) systems.


• Experience within a GMP environment is preferred but not essential.


• Good standard of communication written and orally in English.

About Us:

Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise.

What’s in it for you:

• Highly competitive total reward packages


• Wellbeing programmes


• Development opportunities


• Welcoming, friendly, supportive colleagues


• A diverse and inclusive working environment


• Our values are: Deliver Innovation, Be Inspiring and Have Integrity


• State of the art laboratory and manufacturing facilities

Collaborate. Contribute. Change lives

We offer:

Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).

Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.